Business
US FDA warns Aurobindo Pharma’s Eugia unit in Telangana
The US FDA has issued a warning letter to Unit-I of Eugia Pharma Specialities, Aurobindo Pharma’s wholly owned subsidiary, after an inspection of its Telangana formulation facility. The inspection found four observations and led to an Official Action Indicated status. Aurobindo said existing US supplies are unaffected and the unit contributes about 2% of group revenue.
Reported byThe Public Views
The Public Views
How serious are the FDA compliance issues at Eugia Pharma's facility?
- Minor lapses
- Significant but manageable
- Cannot say without details
Results open up once you vote.
- #pharma
- #regulation
The Public Views - short news, and what people actually think about it.